Natco Pharma Ltd. has received approval from the U.S. Food and Drug Administration for a cancer treatment, marking a significant regulatory milestone for the Indian drugmaker. The clearance allows the company to market the product in the United States, one of the world’s most competitive pharmaceutical markets. Analysts said the approval enhances Natco’s oncology portfolio and could support revenue growth through regulated-market sales.